What Is Cancer Treatment in Korea Really Like in 2026?

We can't provide reviews of individual hospitals or physicians, but the structure of cancer care in Korea, national statistics, and the actual procedures involved are all verifiable through public data. As of 2026, the 5-year relative survival rate for stomach cancer is 78.6% and for liver cancer 40.4% (National Cancer Registry Statistics, 2019–2023), and a systematic process is in place for international patients.

Key Takeaways

• We do not provide reviews or recommendations for specific hospitals or doctors; instead, reliability can be confirmed through national statistics and institutional procedures.
• Korea's 5-year relative survival rate is 78.6% for stomach cancer and 40.4% for liver cancer, both based on National Cancer Registry Statistics 2019–2023 (National Cancer Center), not figures from any individual hospital.
• Institutions that attract international patients must be registered with the Ministry of Health and Welfare, and documents issued by registered institutions serve as the basis for medical-purpose visa review.
• The process runs through eight stages, from initial inquiry to post-return follow-up care. Remote review (pre-arrival review) produces a written opinion within 5 business days once complete records are submitted.
• Starting May 2027, amended legislation will officially permit non-face-to-face consultations and prescriptions for international patients, making post-return care management more systematic.

Why Are Korea's Cancer Treatment Statistics Reliable?

• Korea maintains transparency on survival rates for all cancer types through an official aggregation system called the National Cancer Registry Statistics. This is not a self-reported figure from any particular hospital, but nationwide data compiled by the Central Cancer Registry at the National Cancer Center.
• For stomach cancer, for example, Korea's 5-year relative survival rate is 78.6% (2019–2023), compared to 39.8% in the U.S. SEER statistics (2016–2022). For liver cancer, the figures are 40.4% in Korea versus 21.9% in the U.S. However, these two numbers reflect different measurement periods and differing early-detection rates (Korea runs a national gastroscopy screening program every two years starting at age 40), among other factors, so a simple comparison cannot determine which system is 'better.'
• Survival rates are population averages, not predictors of any individual's outcome. Under Korean medical law, hospital-specific outcome data cannot be used in advertising, and actual treatment results vary significantly based on individual factors such as cancer stage, liver function, and comorbidities.

How Does the Process Work for International Patients?

• Stage 1 — Inquiry (1–3 days): Contact a coordinator desk and receive a response within 24 hours; consultation booking is free.
• Stage 2 — Remote review / pre-arrival review (5 business days once records are complete): Imaging, biopsy results, and diagnostic reports are sent to medical staff at a tertiary hospital for a written opinion. The review fee is KRW 1,000,000 (about US$730), which is deducted from treatment costs if a treatment contract is signed.
• Stage 3 — Booking and contract (3–7 days): A video consultation is used to finalize the treatment plan with the hospital, and a confirmed appointment document is issued.
• Stage 4 — Visa: Short-term treatment under 90 days uses visa code C-3-3; treatment exceeding 90 days uses G-1-10. Invitation documents from a registered host institution form the basis for visa review, though approval and duration remain at the discretion of the relevant overseas diplomatic mission and cannot be assured in advance.
• Stages 5–8 — Entry into Korea, examination and treatment, recovery and return home, and follow-up care. Upon return, patients receive an English-language medical summary and handover document so that local physicians can continue care.

FAQ — Can you recommend a specific hospital or doctor?

We do not provide recommendations or reviews naming specific hospitals or individual medical staff. Instead, during the remote review stage, we compare three hospitals that match the patient's symptoms and records, and provide a package estimate alongside the comparison.

FAQ — Are the survival rate statistics from a specific hospital?

No. Both the 78.6% figure for stomach cancer and the 40.4% figure for liver cancer are nationwide statistics from the National Cancer Registry Statistics 2019–2023 (Central Cancer Registry, National Cancer Center), not the treatment results of any individual hospital. Under Korean medical law, hospital-specific outcome disclosures cannot be used for advertising purposes.

FAQ — Can patients receive care after returning home?

Yes. Patients can receive an English-language medical summary, copies of imaging, copies of prescriptions, and a handover document noting the timing of the next examination. Starting in May 2027, per an announcement from the Ministry of Health and Welfare, non-face-to-face consultations and prescriptions for international patients will be officially permitted under law (as reported by Money Today, dated 2026-05-26). Even before then, many hospitals operate post-treatment consultation services through their international patient service desks.

Sources and Notes

• This article was written based on National Cancer Registry Statistics 2019–2023 (National Cancer Center), SEER statistics, HiKorea visa guidance, Ministry of Health and Welfare and Medical Korea materials, and Money Today reporting (2026-05-26).
• This content is intended for general medical information purposes only. Diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Please consult directly with medical professionals to determine an accurate diagnosis and treatment plan.